Tech Company Financing Transactions
Taysha Gene Therapies Funding Round
Taysha Gene Therapies, based in Dallas, secured $95 million from Fidelity Management & Research Company, ArrowMark Partners and BlackRock.
Transaction Overview
Company Name
Announced On
8/7/2020
Transaction Type
Venture Equity
Amount
$95,000,000
Round
Series B
Investors
Proceeds Purpose
Proceeds from the Series B financing will be used to advance the initial cohort of lead programs into the clinic, accelerate progress on anticipated IND submissions, build a commercially scalable GMP manufacturing facility and continue development of the company's extensive portfolio of potentially curative gene therapies in partnership with the UT Southwestern Gene Therapy Program.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
2280 Inwood Rd.
Dallas, TX 75235
USA
Dallas, TX 75235
USA
Phone
Undisclosed
Website
Email Address
Overview
At Taysha Gene Therapies (Nasdaq: TSHA), we're on a mission to eradicate monogenic CNS disease for rare and large market indications. We are singularly focused on developing curative medicines. Through our proven experience in gene therapy and our unrivaled alliance with the UT Southwestern Gene Therapy Program, we are able to rapidly translate our treatments from early discovery into the clinic.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Claire Aldridge
Browse more venture capital transactions:
Prev: 8/6/2020: Bryn Pharma venture capital transaction
Next: 8/7/2020: Big Run Studios venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on all VC transactions involving tech companies. VC investment data records on this site are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs